Career Possibilities Panel & Speed Networking - Venture & Growth including Entrepreneurship, Fundraising, Development, & VCAs the STEM landscape continues to evolve, professionals are increasingly embracing non-linear career paths that reflect their expanding skills, interests, and goals. This series is designed to support STEM professionals navigating career shifts—whether exploring new sectors, pursuing leadership roles, or transitioning into emerging fields. The panel will have an informational interview type feel with panelists sharing their career paths, a look at what their job entails, and transferable skills for those looking to make a change. The panel will be moderated by Peng Meng Kou, Director of Business Development at Hengrui USA. Panelists include:
Date and Time: Agenda: Location: Cost: Given our mission is to promote women's development in STEM we would like to offer a free spot in our workshops to those in transition between jobs or who cannot afford the ticket price. Please contact [email protected] if you qualify.
Register HereSpecial thank you to our sponsor:
Panelist Bios: Aimee Raleigh is a principal at Atlas Venture where she works alongside stellar entrepreneurs to build companies focused on innovative therapies and exciting new biology. Aimee serves as a board director at Travin Bio and several stealth newcos. She is a board observer at Triveni Bio, Vima Therapeutics, and Remix Therapeutics. She was previously an observer at Kailera Therapeutics (NASDAQ: KLRA), Aiolos Bio (acquired by GSK) and Versanis Bio (acquired by Eli Lilly). Prior to joining Atlas, Aimee was a life sciences consultant at L.E.K. Consulting. At L.E.K., she worked with pharmaceutical and biotechnology clients on strategy for early-stage therapies, including asset diligence, pipeline and indication prioritization, and commercial planning. Aimee received her Ph.D. in bioengineering from the University of California, San Diego, where she was mentored by Dr. Robert Sah and Dr. Gary Firestein. Her doctoral work focused on modeling biophysical mechanisms of disrupted synovial joint lubricant homeostasis in post-traumatic osteoarthritis. Aimee received her B.S.E. in biomedical engineering from Duke University, where she researched cell migration in response to chemokine gradients. Aimee now serves on the Duke Boston board. Sabrina Yang is Vice President, Global Initiatives at Flagship Pioneering. She is leading Flagship Pioneering's China strategy and forging institutional partnerships to accelerate innovation and medicines for patients globally. Prior that she led a Flagship-founded bio platform companies from seed through Series B. Co-founded Empress Therapeutics and FL91 (now Ampersand Biomedicines). There she was responsible for NewCo R&D strategy, business development, IP strategy, team formation, company milestones, platform proof points, developing budget, and interfacing with board members, scientific advisors, and consultants. Before that her focus was bioplatform company creation. She was Doctoral Researcher at Massachusetts Institute of Technology in the laboratory of Dr. Darrell Irvine (HHMI investigator) at the Koch Institute of Integrative Cancer Research. She received her Ph.D., Materials Science and Engineering from Massachusetts Institute of Technology.
|
